A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
about
Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasisDiagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.The role of cell-free DNA in predicting colorectal cancer prognosis.
P2860
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@ast
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@en
type
label
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@ast
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@en
prefLabel
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@ast
A randomized phase 3 study on ...... g within Chemotherapy Scheme).
@en
P2093
P2860
P50
P1433
P1476
A randomized phase 3 study on ...... ng within Chemotherapy Scheme)
@en
P2093
Alessandro Bertolini
Biagio Pecori
Carmela Romano
Chiara Carlomagno
Ciro Gallo
Corradina Caracò
Elisabetta de Lutio di Castelguidone
Ernesta Cavalcanti
Francesco Perrone
Gerardo Rosati
P2860
P2888
P356
10.1186/S12885-016-2102-Y
P407
P50
P577
2016-02-08T00:00:00Z
P5875
P6179
1048107871